Moore Capital Management, LP Biomarin Pharmaceutical Inc Transaction History

Moore Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $744,300 - $922,200	-10,000 Reduced 3.85%	250,000 $20.6 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $4.19 Million - $4.95 Million	50,000 Added 23.81%	260,000 $22.7 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $1.13 Million - $1.46 Million	14,800 Added 7.58%	210,000 $20.2 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $2.99 Million - $3.33 Million	35,200 Added 22.0%	195,200 $17.3 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $11.3 Million - $13 Million	130,000 Added 433.33%	160,000 $13.9 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $8.77 Million - $11.7 Million	-100,000 Reduced 76.92%	30,000 $2.92 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $6.15 Million - $8.26 Million	76,012 Added 140.79%	130,000 $13.5 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $1.69 Million - $1.99 Million	-20,576 Reduced 27.6%	53,988 $4.58 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $1.23 Million - $1.49 Million	17,207 Added 30.0%	74,564 $6.18 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $8.52 Million - $10.6 Million	-114,714 Reduced 66.67%	57,357 $4.42 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $12.3 Million - $15.7 Million	172,071 New	172,071 $15.2 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.